FDA Approves Novartis' Lutathera for Pediatric Patients with Gastroenteropancreatic Neuroendocrine Tumors

Posted on by admin
1 min read

Lutathera is the first FDA-approved treatment for younger patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Avatar for admin
admin https://goorre.com

You May Also Like

More From Author

+ There are no comments

Add yours